Majority of these are SDH deficient. For these patients, if a clinical trial is available, that would be preferable. From a SOC standpoint, EU investigators have data on Regorafenib. For the rare WT GIST with B-raf mutation or NTRK fusion, appropriate targeted therapy would be indicated.